Patents by Inventor Christopher M. Yates

Christopher M. Yates has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METALLOENZYME INHIBITOR COMPOUNDS
    Publication number: 20260124204
    Abstract: Provided are compounds having HDAC6 modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by HDAC6.
    Type: Application
    Filed: June 9, 2025
    Publication date: May 7, 2026
    Applicant: Eikonizo Therapeutics, Inc.
    Inventor: Christopher M. Yates
  • TYK2 DEGRADERS AND USES THEREOF
    Publication number: 20260125400
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: April 19, 2024
    Publication date: May 7, 2026
    Inventors: Isaac Marx, Xiao Zhu, Christopher M. Yates, Bin Yang, Xiaozhang Zheng, Michael D. Sintchak, Yi Zhang, Matthew M. Weiss, Lewis Dale Pennington, Nan Ji, Eamon Comer, Melissa Ford
  • METALLOENZYME INHIBITOR COMPOUNDS
    Publication number: 20260097034
    Abstract: Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
    Type: Application
    Filed: October 2, 2025
    Publication date: April 9, 2026
    Inventors: Steven Sparks, Christopher M. Yates, Sammy R. Shaver, William J. Hoekstra
  • Metalloenzyme inhibitor compounds
    Patent number: 12458642
    Abstract: Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders, or symptoms thereof mediated by such metalloenzymes. In some embodiments, a provided compound is a compound of Formula I, or a pharmaceutically acceptable salt thereof. In some embodiments, a provided method is a method of alleviating or abating a disorder or disease associated with aldosterone synthase (CYP11B2) or ameliorating a symptom thereof.
    Type: Grant
    Filed: June 17, 2021
    Date of Patent: November 4, 2025
    Assignee: Corxel Pharmaceuticals Hong Kong Limited
    Inventors: Steven Sparks, Christopher M. Yates, Sammy R. Shaver, William J. Hoekstra
  • METALLOENZYME INHIBITOR COMPOUNDS
    Publication number: 20250296925
    Abstract: Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
    Type: Application
    Filed: June 10, 2025
    Publication date: September 25, 2025
    Inventors: Steven Sparks, Christopher M. Yates
  • INHIBITING HISTONE DEACETYLASE 6 (HDAC6)
    Publication number: 20250250263
    Abstract: Provided herein are compounds that selectively inhibit HDAC6, a protein whose activity is associated with a variety of diseases (e.g., cancer, neurological disorders). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating HDAC6-related diseases and disorders (e.g., Alzheimer's disease, cancer) with the compounds in a subject, by administering the compounds and/or compositions described herein.
    Type: Application
    Filed: April 7, 2023
    Publication date: August 7, 2025
    Applicant: Eikonizo Therapeutics, Inc.
    Inventors: Florence Fevrier Wagner, Christopher M. Yates, Thomas Edward Richardson
  • Metalloenzyme inhibitor compounds
    Patent number: 12370194
    Abstract: Provided are compounds having HDAC6 modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by HDAC6.
    Type: Grant
    Filed: February 16, 2024
    Date of Patent: July 29, 2025
    Assignee: Eikonizo Therapeutics, Inc.
    Inventor: Christopher M. Yates
  • Metalloenzyme inhibitor compounds
    Patent number: 12358893
    Abstract: Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
    Type: Grant
    Filed: January 8, 2020
    Date of Patent: July 15, 2025
    Assignee: Corxel Pharmaceuticals Hong Kong Limited
    Inventors: Steven Sparks, Christopher M. Yates
  • PROTEIN DEGRADERS AND USES THEREOF
    Publication number: 20250214969
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same for the targeted degradation of proteins, and the treatment of target protein-mediated disorders.
    Type: Application
    Filed: March 31, 2023
    Publication date: July 3, 2025
    Inventors: Bin YANG, Xiaozhang ZHENG, Michael D. SINTCHAK, Matthew M. WEISS, Christopher M. YATES, Yi ZHANG, Xiao ZHU, Lewis Dale PENNINGTON, Nan JI
  • IRAK DEGRADERS AND USES THEREOF
    Publication number: 20250205342
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same.
    Type: Application
    Filed: March 31, 2023
    Publication date: June 26, 2025
    Inventors: Bin YANG, Xiaozhang ZHENG, Michael D. SINTCHAK, Matthew M. WEISS, Christopher M. YATES, Yi ZHANG, Xiao ZHU, Lewis Dale PENNINGTON, Nan JI
  • TYK2 DEGRADERS AND USES THEREOF
    Publication number: 20250051338
    Abstract: The present invention provides compounds, compositions thereof, and methods of using the same. Compounds and compositions thereof that are useful, for example, for targeting, inhibiting, and/or degrading TYK2. In certain embodiments, provided are TYK2 inhibitors and/or degraders and methods of making same. More specifically, TYK2 degraders, compositions which comprise TYK2 degraders, and methods of treating TYK2-associated conditions are provided.
    Type: Application
    Filed: October 24, 2022
    Publication date: February 13, 2025
    Inventors: Isaac MARX, Christopher M. YATES, Xiao ZHU, Lewis Dale PENNINGTON, Eamon COMER, Melissa FORD
  • METALLOENZYME INHIBITOR COMPOUNDS
    Publication number: 20240307391
    Abstract: Provided are compounds having HDAC6 modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by HDAC6.
    Type: Application
    Filed: February 16, 2024
    Publication date: September 19, 2024
    Applicant: Eikonizo Therapeutics, Inc.
    Inventor: Christopher M. Yates
  • Metalloenzyme inhibitor compounds
    Patent number: 11938134
    Abstract: Provided are compounds having HDAC6 modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by HDAC6.
    Type: Grant
    Filed: June 2, 2021
    Date of Patent: March 26, 2024
    Assignee: Eikonizo Therapeutics, Inc.
    Inventor: Christopher M. Yates
  • Metalloenzyme inhibitor compounds
    Patent number: 11919883
    Abstract: Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
    Type: Grant
    Filed: August 31, 2021
    Date of Patent: March 5, 2024
    Assignee: Ji Xing Pharmaceuticals Hong Kong Limited
    Inventors: Steven Sparks, Christopher M. Yates, Sammy R. Shaver
  • METALLOENZYME INHIBITOR COMPOUNDS
    Publication number: 20220088018
    Abstract: Provided are compounds having HDAC6 modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by HDAC6.
    Type: Application
    Filed: June 2, 2021
    Publication date: March 24, 2022
    Applicant: Eikonizo Therapeutics, Inc.
    Inventor: Christopher M. Yates
  • METALLOENZYME INHIBITOR COMPOUNDS
    Publication number: 20220081420
    Abstract: Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
    Type: Application
    Filed: January 8, 2020
    Publication date: March 17, 2022
    Inventors: Steven SPARKS, Christopher M. YATES
  • METALLOENZYME INHIBITOR COMPOUNDS
    Publication number: 20220009907
    Abstract: Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
    Type: Application
    Filed: August 31, 2021
    Publication date: January 13, 2022
    Inventors: Steven SPARKS, Christopher M. YATES, Sammy R. SHAVER
  • ANTIFUNGAL COMPOUNDS
    Publication number: 20210360921
    Abstract: The present invention relates to compounds of Formula (I): wherein R1 is as defined herein, or an acceptable salt, solvate, prodrug or hydrate thereof. The compounds of Formula I are inhibitors of metalloenzymes, such as lanosterol demethylase (CYP51).
    Type: Application
    Filed: June 3, 2021
    Publication date: November 25, 2021
    Applicant: Mycovia Pharmaceuticals, Inc.
    Inventors: William J. Hoekstra, Christopher M. Yates, Robert J. Schotzinger, Michael R. Loso, Gary D. Gustafson, Michael T. Sullenberger, Kimberly Steward, Javier Delgado, Xuelin Wang
  • METALLOENZYME INHIBITOR COMPOUNDS
    Publication number: 20210322409
    Abstract: Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
    Type: Application
    Filed: June 17, 2021
    Publication date: October 21, 2021
    Inventors: Steven SPARKS, Christopher M. YATES, Sammy R. SHAVER, William J. HOEKSTRA
  • Metalloenzyme inhibitor compounds
    Patent number: 11136309
    Abstract: Provided are compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: October 5, 2021
    Assignee: PHASEBIO PHARMACEUTICALS, INC.
    Inventors: Steven Sparks, Christopher M. Yates, Sammy R. Shaver